Bile acid-based advanced drug delivery systems, bilosomes and micelles as novel carriers for therapeutics.
antidiabetic drug
bile acid
bilosome
drug delivery
micelle
Journal
Cell biochemistry and function
ISSN: 1099-0844
Titre abrégé: Cell Biochem Funct
Pays: England
ID NLM: 8305874
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
revised:
07
06
2022
received:
31
12
2021
accepted:
11
06
2022
pubmed:
14
7
2022
medline:
23
8
2022
entrez:
13
7
2022
Statut:
ppublish
Résumé
Diabetes mellitus affects almost half a billion patients worldwide and results from either destruction of β-cells responsible for insulin secretion or increased tissue resistance to insulin stimulation and the reduction of glycemic control. Novel drug delivery systems can improve treatment efficacy in diabetic patients. The low aqueous solubility of most oral antidiabetic drugs decreases drug bioavailability; therefore, there is a demand for the use of novel methods to overcome this issue. The application of bile acids mixed micelles and bilosomes can provide an enhancement in drug efficacy. Bile acids are amphiphilic steroidal molecules that contain a saturated tetracyclic hydrocarbon cyclopentanoperhydrophenanthrene ring, and consist of three 6-membered rings and a 5-membered ring, a short aliphatic side chain, and a tough steroid nucleus. This review offers a comprehensive and informative data focusing on the great potential of bile acid, their salts, and their derivatives for the development of new antidiabetic drug delivery system.
Substances chimiques
Bile Acids and Salts
0
Drug Carriers
0
Micelles
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
623-635Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Palekar-Shanbhag P, Lande S, Chandra R, Rane D. Bilosomes: superior vesicular carriers. Curr Drug Ther. 2020;15(4):312-320.
Deng F, Bae YH. Bile acid transporter-mediated oral drug delivery. J Controlled Release. 2020;327:100-116.
Zhao R, Lu Z, Yang J, Zhang L, Li Y, Zhang X. Drug delivery system in the treatment of diabetes mellitus. Front Bioeng Biotechnol. 2020;8:880.
Cole JB, Florez JC. Genetics of diabetes mellitus and diabetes complications. Nat Rev Nephrol. 2020;16(7):377-390.
Yaribeygi H, Sathyapalan T, Atkin SL, Sahebkar A. Molecular mechanisms linking oxidative stress and diabetes mellitus. Oxid Med Cell Longev. 2020;2020:8609213.
Quandt Z, Young A, Anderson M. Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes. Clin Exp Immunol. 2020;200(2):131-140.
Nair GG, Tzanakakis ES, Hebrok M. Emerging routes to the generation of functional β-cells for diabetes mellitus cell therapy. Nat Rev Endocrinol. 2020:1-13.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Suppl_1):S81-S90.
Meneses MJ, Silva BM, Sousa M, Sa R, Oliveira PF, Alves MG. Antidiabetic drugs: mechanisms of action and potential outcomes on cellular metabolism. Curr Pharm Des. 2015;21(25):3606-3620.
Mikov M, Pavlović N, Stanimirov B, et al. DPP-4 inhibitors: renoprotective potential and pharmacokinetics in type 2 diabetes mellitus patients with renal impairment. Eur J Drug Metab Pharmacokinet. 2020;45(1):1-14.
Nauck MA, Wefers J, Meier JJ. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. Lancet Diabetes Endocrinol. 2021;9(8):525-544.
Zimmet P, Cowie C, Ekoe JM, Shaw J. Classification of diabetes mellitus and other categories of glucose intolerance. In: DeFronzo RA, Ferranini E, Keen H, Zimmet P, eds. International Textbook of Diabetes Mellitus. John Wiley & Sons; 2004:3-14.
Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med. 1994;331(21):1428-1436.
Zimmet P, Alberti K, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414(6865):782-787.
Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med. 2001;161(13):1653-1659.
Galicia-Garcia U, Benito-Vicente A, Jebari S, et al. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci. 2020;21(17):6275.
Petznick AM. Identifying and addressing barriers to insulin acceptance and adherence in patients with type 2 diabetes mellitus. J Osteopath Med. 2013;113(s42):6-16.
Yaturu S. Insulin therapies: current and future trends at dawn. World J Diabetes. 2013;4(1):1-7.
Arbit E. The physiological rationale for oral insulin administration. Diabetes Technol Ther. 2004;6(4):510-517.
Sadrzadeh N, Glembourtt MJ, Stevenson CL. Peptide drug delivery strategies for the treatment of diabetes. J Pharm Sci. 2007;96(8):1925-1954.
Alai MS, Lin WJ, Pingale SS. Application of polymeric nanoparticles and micelles in insulin oral delivery. J Food Drug Anal. 2015;23(3):351-358.
Xu Y, Michalowski CB, Beloqui A. Advances in lipid carriers for drug delivery to the gastrointestinal tract. Curr Opin Colloid Interface Sci. 2020;52:101414.
Hirlekar RS. Oral insulin delivery: novel strategies. Asian J Pharm. 2017;11:03.
Shen D, Yu H, Wang L, et al. Recent progress in design and preparation of glucose-responsive insulin delivery systems. J Controlled Release. 2020;321:236-258.
Sindhu A, Bharath S, Furtado S, Deveswaran R, Basavaraj B. Development of and advances in insulin delivery. SA Pharm J. 2011;78(6):32-37.
Wong CY, Al-Salami H, Dass CR. Microparticles, microcapsules and microspheres: a review of recent developments and prospects for oral delivery of insulin. Int J Pharm. 2018;537(1-2):223-244.
Watson AJ, Duckworth CA, Guan Y, Montrose MH. Mechanisms of epithelial cell shedding in the mammalian intestine and maintenance of barrier function. Ann NY Acad Sci. 2009;1165(1):135-142.
Xiao Y, Tang Z, Wang J, et al. Oral insulin delivery platforms: strategies to address the biological barriers. Angew Chem Int Ed. 2020;59(45):19787-19795.
Evans D, Pye G, Bramley R, Clark A, Dyson T, Hardcastle J. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut. 1988;29(8):1035-1041.
Guengerich FP. Human cytochrome P450 enzymes. In: Ortiz de Montellano PR, ed. Cytochrome P450. Springer; 2005:377-530.
Hadiya S, Radwan R, Zakaria M, El-Sherif T, Hamad MA, Elsabahy M. Nanoparticles integrating natural and synthetic polymers for in vivo insulin delivery. Pharm Dev Technol. 2021;26(1):30-40.
Zhang T, Tang JZ, Fei X, et al. Can nanoparticles and nano-protein interactions bring a bright future for insulin delivery? Acta Pharm Sin B. 2020;11(3):651-667.
Sabu C, Pramod K. Advanced nanostructures for oral insulin delivery. In: Kumar Daima H, PN N, Ranjan Sd, Dasgupta N, Lichtfouse E, eds. Nanoscience Medicine. Vol 1. Springer; 2020:187-212.
Kuhajda K, Kandrac J, Kevresan S, Mikov M, Fawcett J. Structure and origin of bile acids: an overview. Eur J Drug Metab Pharmacokinet. 2006;31(3):135-143.
Ridlon JM, Harris SC, Bhowmik S, Kang D-J, Hylemon PB. Consequences of bile salt biotransformations by intestinal bacteria. Gut Microbes. 2016;7(1):22-39.
Nafiujjaman M, Shahriar SS, Hasan MN. Bile acid-inspired oral small molecules drug delivery. In: Nurunnabi Md. ed. Bioinspired and Biomimetic Materials for Drug Delivery. Elsevier; 2021:171-186.
Yamamoto A, Taniguchi T, Rikyuu K, et al. Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm Res. 1994;11(10):1496-1500.
Li Y, Shao Z, Mitra AK. Dissociation of insulin oligomers by bile salt micelles and its effect on α-chymotrypsin-mediated proteolytic degradation. Pharm Res. 1992;9(7):864-869.
Pavlović N, Goločorbin-Kon S, Ðanić M, et al. Bile acids and their derivatives as potential modifiers of drug release and pharmacokinetic profiles. Front Pharmacol. 2018;9:1283.
Taoka H, Yokoyama Y, Morimoto K, et al. Role of bile acids in the regulation of the metabolic pathways. World J Diabetes. 2016;7(13):260-270.
Gerhard GS, Styer AM, Wood GC, et al. A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. Diabetes Care. 2013;36(7):1859-1864.
Kohli R, Bradley D, Setchell KD, Eagon JC, Abumrad N, Klein S. Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. J Clin Endocrinol Metab. 2013;98(4):E708-E712.
Rabiee A, Magruder JT, Salas-Carrillo R, et al. Hyperinsulinemic hypoglycemia after Roux-en-Y gastric bypass: unraveling the role of gut hormonal and pancreatic endocrine dysfunction. J Surg Res. 2011;167(2):199-205.
Sharma D, Soni M, Kumar S, Gupta G. Solubility enhancement-eminent role in poorly soluble drugs. Res J Pharm Technol. 2009;2(2):220-224.
Savjani KT, Gajjar AK, Savjani JK. Drug solubility: importance and enhancement techniques. ISRN Pharm. 2012;2012:195727.
Meaney C, O'driscoll C. A comparison of the permeation enhancement potential of simple bile salt and mixed bile salt: fatty acid micellar systems using the CaCo-2 cell culture model. Int J Pharm. 2000;207(1-2):21-30.
Dial EJ, Rooijakkers SH, Darling RL, Romero JJ, Lichtenberger LM. Role of phosphatidylcholine saturation in preventing bile salt toxicity to gastrointestinal epithelia and membranes. J Gastroenterol Hepatol. 2008;23(3):430-436.
Hildebrand A, Beyer K, Neubert R, Garidel P, Blume A. Temperature dependence of the interaction of cholate and deoxycholate with fluid model membranes and their solubilization into mixed micelles. Colloids Surf B. 2003;32(4):335-351.
Martin GP, Marriott C. Membrane damage by bile salts: the protective function of phospholipids. J Pharm Pharmacol. 1981;33(1):754-759.
Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6(3):231-248.
Westergaard H, Dietschy JM. The mechanism whereby bile acid micelles increase the rate of fatty acid and cholesterol uptake into the intestinal mucosal cell. J Clin Invest. 1976;58(1):97-108.
Mazzanti R, Fantappié O, Kamimoto Y, Gatmaitan Z, Gentilini P, Arias IM. Bile acid inhibition of P-glycoprotein-mediated transport in multidrug-resistant cells and rat liver canalicular membrane vesicles. Hepatology. 1994;20(1):170-176.
Yang L, Fawcett JP, Østergaard J, Zhang H, Tucker IG. Mechanistic studies of the effect of bile salts on rhodamine 123 uptake into RBE4 cells. Mol Pharm. 2012;9(1):29-36.
Zhu Y, Yu J, Tong S, et al. Preparation and in vitro evaluation of povidone-sodium cholate-phospholipid mixed micelles for the solubilization of poorly soluble drugs. Arch Pharm Res. 2010;33(6):911-917.
Hendradi E, Obata Y, Isowa K, Nagai T, Takayama K. Effect of mixed micelle formulations including terpenes on the transdermal delivery of diclofenac. Biol Pharm Bull. 2003;26(12):1739-1743.
Moghimipour E, Ameri A, Handali S. Absorption-enhancing effects of bile salts. Molecules. 2015;20(8):14451-14473.
Dong F, Xie Y, Qi J, et al. Bile salt/phospholipid mixed micelle precursor pellets prepared by fluid-bed coating. Int J Nanomed. 2013;8:1653-1663.
Banik BL, Fattahi P, Brown JL. Polymeric nanoparticles: the future of nanomedicine. Wiley Interdisc Rev Nanomed Nanobiotechnol. 2016;8(2):271-299.
Elnaggar YS. Multifaceted applications of bile salts in pharmacy: an emphasis on nanomedicine. Int J Nanomed. 2015;10:3955.
Chan JM, Valencia PM, Zhang L, Langer R, Farokhzad OC. Polymeric nanoparticles for drug delivery. In: Grobmyer SR, Moudgil BM, eds. Cancer Nanotechnology. Springer; 2010:163-175.
Tolle-Sander S, Lentz KA, Maeda DY, Coop A, Polli JE. Increased acyclovir oral bioavailability via a bile acid conjugate. Mol Pharm. 2004;1(1):40-48.
Kramer W, Wess G, Schubert G, et al. Liver-specific drug targeting by coupling to bile acids. J Biol Chem. 1992;267(26):18598-18604.
Kågedahl M, Swaan PW, Redemann CT, et al. Use of the intestinal bile acid transporter for the uptake of cholic acid conjugates with HIV-1 protease inhibitory activity. Pharm Res. 1997;14(2):176-180.
Kramer W, Wess G, Enhsen A, et al. Modified bile acids as carriers for peptides and drugs. J Controlled Release. 1997;46(1-2):17-30.
Kim D-C, Harrison AW, Ruwart MJ, et al. Evaluation of the bile acid transporter in enhancing intestinal permeability to renin-inhibitory peptides. J Drug Target. 1993;1(4):347-359.
Swaan PW, Hillgren KM, Szoka FC, Øie S. Enhanced transepithelial transport of peptides by conjugation to cholic acid. Bioconjug Chem. 1997;8(4):520-525.
Sreekanth V, Pal S, Kumar S, et al. Self-assembled supramolecular nanomicelles from a bile acid-docetaxel conjugate are highly tolerable with improved therapeutic efficacy. Biomater Sci. 2021;9:5626-5639.
Schubert R, Jaroni H, Schoelmerich J, Schmidt K. Studies on the mechanism of bile salt-induced liposomal membrane damage. Digestion. 1983;28(3):181-190.
Conacher M, Alexander J, Brewer JM. Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine. 2001;19(20-22):2965-2974.
Chilkwar R, Nanjwade B, Nwaji M, Idris S, Mohamied A. Bilosomes based drug delivery system. J Chem Appl. 2015;2(1):5.
Csaba N, Garcia-Fuentes M, Alonso MJ. The performance of nanocarriers for transmucosal drug delivery. Expert Opin Drug Delivery. 2006;3(4):463-478.
Shukla A, Katare O, Singh B, Vyas SP. M-cell targeted delivery of recombinant hepatitis B surface antigen using cholera toxin B subunit conjugated bilosomes. Int J Pharm. 2010;385(1-2):47-52.
Shukla A, Khatri K, Gupta PN, Goyal AK, Mehta A, Vyas SP. Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes). J Pharm Pharm Sci. 2008;11(1):59-66.
Shukla A, Singh B, Katare O. Significant systemic and mucosal immune response induced on oral delivery of diphtheria toxoid using nano-bilosomes. Br J Pharmacol. 2011;164(2b):820-827.
Wilkhu JS, McNeil SE, Anderson DE, Perrie Y. Characterization and optimization of bilosomes for oral vaccine delivery. J Drug Target. 2013;21(3):291-299.
Mann JF, Scales HE, Shakir E, et al. Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity. Methods. 2006;38(2):90-95.
Aburahma MH. Bile salts-containing vesicles: promising pharmaceutical carriers for oral delivery of poorly water-soluble drugs and peptide/protein-based therapeutics or vaccines. Drug Delivery. 2016;23(6):1847-1867.
Mohsen AM, Asfour MH, Salama AA. Improved hepatoprotective activity of silymarin via encapsulation in the novel vesicular nanosystem bilosomes. Drug Dev Ind Pharm. 2017;43(12):2043-2054.
El Menshawe SF, Aboud HM, Elkomy MH, Kharshoum RM, Abdeltwab AM. A novel nanogel loaded with chitosan decorated bilosomes for transdermal delivery of terbutaline sulfate: artificial neural network optimization, in vitro characterization and in vivo evaluation. Drug Delivery Transl Res. 2020;10(2):471-485.
Wang L, Huang X, Jing H, Ma C, Wang H. Bilosomes as effective delivery systems to improve the gastrointestinal stability and bioavailability of epigallocatechin gallate (EGCG). Food Res Int. 2021;149:110631.
Mosallam S, Sheta NM, Elshafeey AH, Abdelbary AA. Fabrication of highly deformable bilosomes for enhancing the topical delivery of terconazole: in vitro characterization, microbiological evaluation, and in vivo skin deposition study. AAPS PharmSciTech. 2021;22(2):1-12.
Velpula A, Jukanti R, Janga KY, et al. Proliposome powders for enhanced intestinal absorption and bioavailability of raloxifene hydrochloride: effect of surface charge. Drug Dev Ind Pharm. 2013;39(12):1895-1906.
Fu Q, Fu H-L, Huan L, et al. Preparation of cefquinome sulfate proliposome and its pharmacokinetics in rabbit. Iran J Pharm Res. 2013;12(4):611.
Bansal S, Kashyap CP, Aggarwal G, Harikumar S. A comparative review on vesicular drug delivery system and stability issues. Int J Res Pharm Chem. 2012;2(3):704-713.
Song K-H, Chung S-J, Shim C-K. Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts. J Controlled Release. 2005;106(3):298-308.
Haritha P, Lakshmi P. Probilosomes: a novel bile salt containing nanocarrier for enhancing oral bioavailability. Int J Pharm Investig. 2020;10(1):49-53.
Jain S, Harde H, Indulkar A, Agrawal AK. Improved stability and immunological potential of tetanus toxoid containing surface engineered bilosomes following oral administration. Nanomed Nanotechnol Biol Med. 2014;10(2):431-440.
Shukla A, Mishra V, Kesharwani P. Bilosomes in the context of oral immunization: development, challenges and opportunities. Drug Discov Today. 2016;21(6):888-899.
Parashar P, Rana P, Dwivedi M, Saraf SA. Dextrose modified bilosomes for peroral delivery: improved therapeutic potential and stability of silymarin in diethylnitrosamine-induced hepatic carcinoma in rats. J Liposome Res. 2019;29(3):251-263.
Wong CY, Al-Salami H, Dass CR. Recent advancements in oral administration of insulin-loaded liposomal drug delivery systems for diabetes mellitus. Int J Pharm. 2018;549(1-2):201-217.
Niu M, Tan Y, Guan P, et al. Enhanced oral absorption of insulin-loaded liposomes containing bile salts: a mechanistic study. Int J Pharm. 2014;460(1-2):119-130.
Niu M, Lu Y, Hovgaard L, et al. Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose. Eur J Pharm Biopharm. 2012;81(2):265-272.
Niu M, Lu Y, Hovgaard L, Wu W. Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization, and improved protection against enzymatic degradation. Int J Nanomed. 2011;6:1155-1166.
Degim Z, Ünal N, Eşsiz D, Abbasoglu U. The effect of various liposome formulations on insulin penetration across Caco-2 cell monolayer. Life Sci. 2004;75(23):2819-2827.
Hu S, Niu M, Hu F, et al. Integrity and stability of oral liposomes containing bile salts studied in simulated and ex vivo gastrointestinal media. Int J Pharm. 2013;441(1-2):693-700.
Cui M, Wu W, Hovgaard L, Lu Y, Chen D, Qi J. Liposomes containing cholesterol analogues of botanical origin as drug delivery systems to enhance the oral absorption of insulin. Int J Pharm. 2015;489(1-2):277-284.
Bashyal S, Seo J-E, Keum T, Noh G, Choi YW, Lee S. Facilitated permeation of insulin across Tr146 cells by cholic acid derivatives-modified elastic bilosomes. Int J Nanomed. 2018;13:5173-5186.
Martin C, Thongborisute J, Takeuchi H, Yamamoto H, Kawashima Y, Alpar H. Cholesterol-bile salt vesicles as potential delivery vehicles for drug and vaccine delivery. Int J Pharm. 2005;298(2):339-343.
Maitani Y, Asano S, Takahashi S, Nakagaki M, Nagai T. Permeability of insulin entrapped in liposome through the nasal mucosa of rabbits. Chem Pharm Bull. 1992;40(6):1569-1572.
Ayogu I, Ogbonna O, Ayolugbe C, Attama A. Evaluation of the pharmacodynamic activity of insulin from bilosomal formulation. Curr Drug Delivery. 2009;6(4):415-418.
Wu S, Bin W, Tu B, et al. A delivery system for oral administration of proteins/peptides through bile acid transport channels. J Pharm Sci. 2019;108(6):2143-2152.
Kim KS, Kwag DS, Hwang HS, Lee ES, Bae YH. Immense insulin intestinal uptake and lymphatic transport using bile acid conjugated partially uncapped liposome. Mol Pharm. 2018;15(10):4756-4763.
Bashyal S, Seo J-E, Keum T, Noh G, Lamichhane S, Lee S. Development, characterization, and ex vivo assessment of elastic liposomes for enhancing the buccal delivery of insulin. Pharmaceutics. 2021;13(4):565.
Bashyal S, Seo J-E, Choi YW, Lee S. Bile acid transporter-mediated oral absorption of insulin via hydrophobic ion-pairing approach. J Controlled Release. 2021;338:644-661.
Miyake M, Minami T, Hirota M, et al. Novel oral formulation safely improving intestinal absorption of poorly absorbable drugs: utilization of polyamines and bile acids. J Controlled Release. 2006;111(1-2):27-34.
Seedher N, Kanojia M. Micellar solubilization of some poorly soluble antidiabetic drugs: a technical note. AAPS PharmSciTech. 2008;9(2):431-436.
Mooranian A, Zamani N, Takechi R, et al. Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 diabetes. Artif Cells Nanomed Biotechnol. 2018;46(sup3):S748-S754.
Mooranian A, Negrulj R, Takechi R, Mamo J, Al-Sallami H, Al-Salami H. The biological effects of the hypolipidaemic drug probucol microcapsules fed daily for 4 weeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti-inflammatory effects. Drug Deliv Transl Res. 2018;8(3):543-551.
Al-Salami H, Mamo J, Mooranian A, et al. Long-term supplementation of microencapsulated ursodeoxycholic acid prevents hypertension in a mouse model of insulin resistance. Exp Clin Endocrinol Diabetes. 2017;125(1):28-32.
Al-Salami H, Butt G, Tucker I, Mikov M. Influence of the semisynthetic bile acid (MKC) on the ileal permeation of gliclazide in healthy and diabetic rats. Pharmacol Rep. 2008;60(4):532.
Gordon G, Moses A, Silver R, Flier J, Carey M. Nasal absorption of insulin: enhancement by hydrophobic bile salts. Proc Natl Acad Sci USA. 1985;82(21):7419-7423.
Tengamnuay P, Mitra AK. Bile salt-fatty acid mixed micelles as nasal absorption promoters of peptides. II. In vivo nasal absorption of insulin in rats and effects of mixed micelles on the morphological integrity of the nasal mucosa. Pharm Res. 1990;7(4):370-375.
Yamamoto A, Luo A, Dodda-Kashi S, Lee V. The ocular route for systemic insulin delivery in the albino rabbit. J Pharmacol Exp Ther. 1989;249(1):249-255.
Yamamoto A, Hayakawa E, Kato Y, Nishiura A, Lee V. A mechanistic study on enhancement of rectal permeability to insulin in the albino rabbit. J Pharmacol Exp Ther. 1992;263(1):25-31.
Johansson F, Hjertberg E, Eirefelt S, Tronde A, Bengtsson UH. Mechanisms for absorption enhancement of inhaled insulin by sodium taurocholate. Eur J Pharm Sci. 2002;17(1-2):63-71.
Scott-Moncrieff JC, Shao Z, Mitra AK. Enhancement of intestinal insulin absorption by bile salt-fatty acid mixed micelles in dogs. J Pharm Sci. 1994;83(10):1465-1469.
Chauhan S, Singh K, Sundaresan C. Physico-chemical characterization of drug-bio-surfactant micellar system: a road for developing better pharmaceutical formulations. J Mol Liq. 2018;266:692-702.
Lane ME, O'driscoll CM, Corrigan OI. Quantitative estimation of the effects of bile salt surfactant systems on insulin stability and permeability in the rat intestine using a mass balance model. J Pharm Pharmacol. 2005;57(2):169-175.
Schilling RJ, Mitra AK. Intestinal mucosal transport of insulin. Int J Pharm. 1990;62(1):53-64.
Liu J, Gong T, Wang C, Zhong Z, Zhang Z. Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: preparation and characterization. Int J Pharm. 2007;340(1-2):153-162.
Mishra R, Mishra S. Updates in bile acid-bioactive molecule conjugates and their applications. Steroids. 2020;159:108639.
Rajput T, Chauhan MK. Bilosome: a bile salt based novel carrier system gaining interest in pharmaceutical research. J Drug Delivery Ther. 2017;7(5):4-16.